| Protocol ID | NCT01474642 |
| Registration Date | 2011-11-18 |
| Status | completed |
| Sponsor | Samsung Medical Center |
| Country | South Korea |
| Industry | not industry |
| Blinding | unblinded |
| Center Type | singel-center RCT |
| Scope | national RCT |
| First Patient In | 2008-09-01 |
| Last Patient Out | 2014-05-01 |
| Publication | n |
| Gender % | ALL |
| Mean Age | 18 Years - |
NCT01474642
A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Genexol (XG) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma
| Field |
CLAUDE
claude-sonnet-4-20250514 Thinking: claude-opus-4-20250514 4726ms / 10571 tok |
OPENAI
gpt-4o Thinking: o3 4598ms / 8997 tok |
GLM
glm-5.1 11134ms / 9183 tok |
Review |
|---|---|---|---|---|
| rct_type | parallel RCT | parallel RCT | parallel RCT | OK |
| cancer_status | Cancer | Cancer | Cancer | OK |
| non_cancer_spec | N/A | N/A | N/A | OK |
| setting_patient | outpatient | outpatient | outpatient | OK |
| setting_place |
other
other → hospital → other
shaky reasoning✓ Unanimous
Initial: other
Requery: hospital — The trial involves IV chemotherapy administration (cisplatin 75mg/m2 iv, paclitaxel 80mg/m2 iv) requiring hospital-based infusion services for cancer patients with advanced/metastatic disease.
Thinking: other — This is outpatient chemotherapy where patients receive IV infusions at clinic visits and take oral medication at home, not requiring hospital admission.
|
other
hospital → other → other
shaky reasoning✓ Unanimous
Initial: hospital
Requery: other — The intervention involves outpatient administration of chemotherapy drugs (Capecitabine and Cisplatin/Paditaxel), which does not require hospitalization or inpatient admission, fitting 'other' as the setting place.
Thinking: other — IV/PO chemotherapy is administered in an outpatient oncology clinic at Samsung Medical Center, not requiring inpatient admission.
|
other
other → other
shaky reasoning✓ Unanimous
Initial: other
Requery: other — The intervention involves outpatient chemotherapy regimens for advanced cancer, which is delivered in an outpatient clinic or ambulatory care setting rather than requiring inpatient hospital admission.
|
OK |
| feasibility | fully powered RCT | fully powered RCT | fully powered RCT | OK |
| intervention_pharmacologic | yes | yes | yes | OK |
| intervention_chemo_immuno_radio | yes | yes | yes | OK |
| intervention_complementary | no | no | no | OK |
| intervention_device | no | no | no | OK |
| intervention_psychological | no | no | no | OK |
| intervention_complex | no | no | no | OK |
| intervention_acp | no | no | no | OK |
| intervention_music | no | no | no | OK |
| intervention_screening | no | no | no | OK |
| intervention_palliative | no | no | no | OK |
| intervention_education | no | no | no | OK |
| intervention_digital | no | no | no | OK |
| intervention_other | no | no | no | OK |
| outcome_symptom | no | no | no | OK |
| outcome_qol | yes | yes | yes | OK |
| outcome_dignity | no | no | no | OK |
| outcome_cost | no | no | no | OK |
| outcome_other | yes | yes | yes | OK |
| pharmacologic_sub | chemotherapy | chemotherapy | chemotherapy | OK |